樂普醫療(300003.SZ)提供傳染病核酸檢測實驗室一站式整體解決方案
格隆匯5月12日丨樂普醫療(300003.SZ)公佈，公司全面整合融合了旗下樂普科技、艾德康、樂普診斷、愛普益等IVD業務領域研發設計、檢測設備、診斷試劑、檢測服務與系統集成等資源，可以為基層醫院、疾控中心傳染病核酸檢測實驗室建設提供一站式整體解決方案，包括實驗室設計施工、設備安裝、軟件系統集成、人員培訓、管理流程再造、運營維護等。
公司旗下樂普裝備10年以來為全國28個省完成了200多家市縣基層醫院手術室、介入導管室和醫學檢測實驗室“一站式”整體解決方案的共建，形成了完整的實驗室設計、集成和建設的專業團隊，具備了實驗室“一站式”整體解決方案的專業化能力。
公司檢測實驗室“一站式”專業整體解決方案包括：基層醫院實驗室全面設計，提供基於檢測通量、自動化程度和生物安全性不同要求的基礎版、標準版、增強版和智能版醫學生物二級(BLS-2)實驗室個性化設計方案；高效開展實驗室基建施工；根據實驗室檢測規模合理配備全自動核酸提取儀、全自動醫用PCR分析儀和生物安全櫃等設備，並可以提供功能齊全的設備耗材，提供規範設備安裝、全面驗收服務。
此外，還包括制定並優化實驗室管理流程，建立規範的實驗檢測體系和完整的SOP管理質量體系，滿足國家衞健委專業實驗室設置標準和質量體系要求；在保證生物安全和有效個人防護的基礎上，嚴格按照PCR實驗室設置要求，建立安全運營管理標準及規範，實現核酸檢測能力的快速提升；開展實驗室醫務人員培訓；確保實驗室規範運營，為醫院排查、隔離點檢測和社會服務的採樣測試、檢測提供優質的運營維護服務和技術維修保障服務。
公司通過快速提供基層醫院、疾控中心傳染病核酸檢測實驗室“一站式”整體解決方案，將幫助國內合作醫療機構儘快完成實驗室的建設及運營，幫助其迅速達到新冠病毒核酸檢測條件，滿足國內各地區“應檢盡檢、願檢盡檢”的要求，切實維護人民羣眾健康權益。
公司表示，公司通過提供醫療機構傳染病核酸檢測實驗室“一站式”整體解決方案，將有助於全面提升公司IVD設備耗材產業化規模，但實驗室建設規模及合作建設進程存在不達預期的風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
